Lipoproteins in Diabetes Mellitus

Diabetes mellitus has become epidemic on a global scale, and millions of new cases are diagnosed every year. With an estimated 80% of people with diabetes living in disadvantaged regions, and the key roles of lipoproteins in the pathogenesis of the chronic complications of diabetes, this volume will be relevant to many readers globally. It is our intention that the contents will advance knowledge of the readers who will use it to contribute to the reduction of the burden associated with altered lipoproteins in people with diabetes. 

The second edition of this book provides an updated and comprehensive review of the field. The book, which includes many tables and figures, is presented in three main sections: (i) Lipoprotein metabolism, qualitative changes and measurements; (ii) Lipoproteins and the complications of diabetes; and (iii) the treatment of lipoproteins in diabetes. Each chapter from the first edition has been updated, and new topics added. New topicsinclude the links between glycemia and lipoproteins, the role of lipoproteins in ischemic stroke, the diagnosis and management of statin intolerance (which is thought to be more common in people with diabetes) and the use of PCSK9 inhibitors and fish oils in the management of lipoproteins in people with diabetes.  This book is written by an international group of experts in the clinical, laboratory and research aspects of lipoproteins in diabetes.

Lipoproteins in Diabetes Mellitus, 2nd Edition is a comprehensive reference on the clinical and scientific aspects of lipoproteins in diabetes. It is a must-have resource for primary care and specialist clinicians, clinical and basic science researchers and to trainees and students.

Part 1 : Lipoprotein Metabolism, Qualitative Changes and Measurements.- 1. Laboratory Assessment of Lipoproteins in Type 2 Diabetes.- 2. Tools for Assessing Lipoprotein Metabolism in Diabetes Mellitus.- 3. Links Between Glucose and Lipoproteins.- 4. Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 Diabetes.- 5. Lipoprotein metabolism and alterations induced by insulin resistance and diabetes.- 6. The PPAR system in diabetes.- 7. Production And Metabolism Of Triglyceride-Rich Lipoproteins: Impact Of Diabetes.- 8. Triglyceride- And Cholesterol-Rich Remnant Lipoproteins In Risk Of Cardiovascular Disease In Diabetes Mellitus.- 9. HDL Function In Diabetes.- 10. Lipoprotein (a): Metabolism, Pathophysiology and Impact on Diabetes Mellitus.- 11. Lipoprotein Glycation in Diabetes Mellitus.- 12. Lipid:Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes.- Part 2 : Lipoproteins and the Complications of Diabetes.- 13. The Role of Modified Forms of LDL and Corresponding Autoantibodies in the Development of Complications in Diabetes.- 14. Endothelial dysfunction in type 2 diabetes, with an update on new interventions.- 15. Lipoproteins and diabetic kidney disease.- 16. Lipids and Diabetic Retinopathy.- 17. Roles of Extravasated and Modified Plasma Lipoproteins in Diabetic Retinopathy.- 18. The Role Of Lipids And Lipoproteins In Peripheral Neuropathy.- 19. Lipoproteins and Ischemic Stroke in Diabetes.- Part 3 : Lipoprotein Treatment in Diabetes.- 20. About Randomized Clinical Trials Related to Lipoproteins in Diabetes Mellitus.- 21. Effects of Lifestyle (Diet, Plant Sterols, Exercise and Smoking) and Glycemic Control on Lipoproteins in Diabetes.- 22. Statin Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes.- 23. Statin intolerance – An overview for clinicians.- 24. Fibrate Therapy: Impact on Dyslipidemia and Cardiovascular Events in Patients with Diabetes Mellitus Type 2.- 25. EPA and Mixed Omega-3 Fatty Acids: Impact on Dyslipidemia and Cardiovascular Events in Patients With Diabetes.- 26. Cholesterol Absorption Inhibitors (Ezetimibe) and Bile Acid Binding Resins (Colesevelam HCl) as Therapy for Dyslipidemia in Patients with Diabetes Mellitus.- 27. Clinical Efficacy Of Proprotein Convertase Synthase Kexin Type 9 Inhibition In Persons With Diabetes Mellitus.- 28. Clinical Care of Lipids in People with Type 1 diabetes.- 29. Adjunct drug treatment to reduce vascular disease in people with diabetes.- 30. Emerging lipoprotein-related therapeutics for patients with diabetes.- Part 4 : Epidemiology of Diabetes and Diabetic Dyslipidemia.- 31. Diabetes Epidemiology And Its Implications.- 32. Epidemiology, Control, and Cardiovascular Outcomes of Dyslipidemia in Diabetes.

Alicia J. Jenkins, MBBS, MD, FRACP, FRCP  

NHMRC Clinical Trials Centre, University of Sydney

Medical Foundation Building Level 6

92-94 Parramatta Rd

Camperdown, Sydney, 2050, NSW, Australia

alicia.jenkins@sydney.edu.au

Peter P. Toth, MD, PhD, FCCP, FESC, FAHA, FACC

Department of Medicine, Division of Cardiology

Johns Hopkins University School of Medicine

Baltimore, Maryland

USA

Peter.toth@cghmc.com

Alicia J. Jenkins, MBBS, MD, FRACP, FRCP is an endocrinologist and researcher. She is a Professor of Diabetes and Vascular Medicine at the University of Sydney, Australia and has honorary academic appointments at Universities in the USA, UK and Hong Kong. Her higher research degree and ongoing clinical and research relates to lipoproteins in diabetes, (clinical, biochemical and molecular) biomarkers, and to the prediction and prevention of the complications of diabetes.  She and her research team and collaborators undertake clinical and basic research and clinical trials related to diabetes and its complications and to cardiovascular disease.  She is a Chief Investigator on several investigator initiated clinical trials in diabetes, including several related to lipid drugs.  She has over 400 publications, cited over 10,000 times and an H-index of 53.  Alicia has previously worked with Peter Toth to edit the first edition of Lipoproteins in Diabetes Mellitus. Alicia works clinically in Type 1 diabetes clinics and is currently on the International Diabetes Federation Western Pacific Region Executive Council, co-Director of the Australian Cardiovascular Alliance Precision Medicine Flagship, the Lipid Guidelines Committee for the Australian Diabetes Society and President of the diabetes aid organisation Insulin For Life. 

Peter P. Toth, MD, PhD is director of preventive cardiology at theCGH Medical Center in Sterling, Illinois. He is Professor of Clinical Family and Community Medicine at the University of Illinois School of Medicine, Professor of Clinical Medicine at Michigan State University College of Osteopathic Medicine, and Adjunct Associate Professor of Medicine, Division of Cardiology, Johns Hopkins University School of Medicine. Dr. Toth is a past president of the National Lipid Association and American Board of Clinical Lipidology. He is President of the American Society of Preventive Cardiology. Dr. Toth has authored and coauthored over 500 publications in medical and scientific journals and textbooks. He is Series Editor of Springer’s textbook collection in Contemporary Cardiology. He has edited and written 19 textbooks on various aspects of cardiovascular medicine. He has lectured on many topics in cardiovascular medicine throughout the world. His Google Scholar score include 13,125 citations, h-index 58, and i10-index 224.